Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biomarkers predicting response and toxicity to FOLFIRINOX in pancreatic cancer
NL-OMON46821Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Jul 2018
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of oxaliplatin, folinic acid, irinotecan and fluorouracil in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Erasmus MC. Primary endpoints: Differences in SNP expression/profile between responders and non-responders, Differences in ctDNA mutations between responders and non-responders and 8 more. Started Jul 2018; status: active, not recruiting.
02
Drugs
oxaliplatinfolinic acidirinotecanfluorouracil
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON46821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46821.